CEI International Affairs: European Proposal Courses | Click for more info
Follow
More…

Covid-19 Innovation Challenges by Innoget

Hospital & Health Care • Innovation Intermediary • United Kingdom • 91 followers

Follow
More…

Is your organization promoting or looking for innovation or research initiatives to mitigate the Covid-19 outbreak? Email us at covid19@innoget.com to list them.

Latest Open Innovation Opportunities

  • All (34)
  • Innovation Needs (4)
  • Technology Offers (30)

Seeking nurse-led ideas from nurses and nursing students around the world focused on improving COVID-19 patient care

Deadline : 2020-11-24

Nurses have always been critical partners on the frontlines of care, and the backbone of our healthcare system. The COVID-19 pandemic has raised new challenges for nurses and health workers and brought into focus the obstacles that they face around the world, every day. The power of nurse-led innovation and know-how may be more critical than ever when developing potential solutions amid a global crisis. With extensive patient experience, nurses’ ideas have the potential to profoundly improve human health. In connection with our overall commitment to supporting frontline healthcare workers amid the COVID-19 pandemic, Johnson & Johnson is proud to continue the Nurses Innovate QuickFire Challenges series with a new challenge inspired by the NurseHack4Health: COVID-19 Virtual Hackathon where over 500 nurses, healthcare professionals, and tech enthusiasts convened virtually to help ideate potential solutions for COVID-19 health challenges. This QuickFire Challenge is open to all nurse innovators, and aims to help nurture early-stage ideas from the frontlines of COVID-19 by celebrating, supporting, & mentoring the nurse innovators behind them. Introducing the Johnson & Johnson Nurses Innovate QuickFire Challenge in COVID-19 Patient Care together with the American Organization for Nursing LeadershipTM (AONL) and the Society of Nurse Scientists, Innovators, Entrepreneurs, & Leaders (SONSIEL). Nurses from around the world are invited to submit ideas aiming to improve COVID-19 patient care. The nurse innovators with the best idea(s) will receive up to $100,000 in grant funding, mentoring from experts across the Johnson & Johnson Family of Companies, and access to the Johnson & Johnson Innovation – JLABS ecosystem to help bring their ideas to life. As innovators on the frontlines of healthcare, nurses have the power to profoundly change lives. Johnson & Johnson has the scale, resources and know-how to help move them forward. Put these two together, and that changes everything. We have never stopped and never will stop advocating for, elevating and empowering nurses as innovative, critical leaders on the frontline. Learn more about nurses who innovate, and the commitment Johnson & Johnson has made to nurses over the past 120 years at https://nursing.jnj.com/our-commitment. Learn more about how we are supporting front line health workers amid the COVID-19 Pandemic

Seeking nurse-led ideas from nurses and nursing students around the world focused on improving COVID-19 patient care
  • +1 month
  • Hide post

Seeking novel proposals aiming to address and enable healthcare solutions in the post-COVID era

Project Size 250,000 € · Deadline : 2020-10-22

While the implications of the pandemic are still unfolding, countries across the world are preparing for life in the “New Normal.” In this period of transition, forward-thinking innovations aiming to address healthcare challenges are needed more than ever. Through disruption, we must leverage data and health technologies to accelerate potentially life-saving ideas aiming to improve patient care through the uncharted times that lay ahead. That is why Johnson & Johnson Innovation—JLABS (“JLABS”), in collaboration with Seoul Metropolitan Government (“SMG”), Korea Health Industry Development Institute (“KHIDI”), Janssen Korea Ltd., is launching the Seoul Innovation QuickFire Challenge for Healthcare in the New Normal. Up to two innovators with the best ideas aiming to address and enable potential healthcare solutions in the post-COVID era will receive up to KRW150,000,000 (approximately US$125,000[1]) in grant funding, residency at the Seoul Bio Hub, and mentorship and coaching from experts at the Johnson & Johnson Family of Companies. [1] From the KRW150 million grant, each awardee will receive a KRW75 million grant including one-year mandatory residency, which must be used toward the rent and utilities at the Seoul Bio Hub for a year. Estimate based on exchange rate of 0.00083 in June 2020

Seeking novel proposals aiming to address and enable healthcare solutions in the post-COVID era
  • +2 months
  • Hide post

Seeking candidates to apply to the LifeArc COVID-19 Fund

Deadline : 2021-04-03

LifeArc has made available an initial £10M for the identification of therapeutics that can be rapidly deployed to treat COVID-19. The aim is to run trials in patients during the current epidemic. It is anticipated that applications will be for funding to repurpose one or more drugs that are generic, already licensed, or are in late stage development for another indication.

Seeking candidates to apply to the LifeArc COVID-19 Fund
  • +5 months
  • Hide post

Seeking Collaborators for COVID-19 Response (By AireHealth)

Deadline : 2021-04-03

AireHealth is ready to enter the ring and help where we can in support of our national effort to stem the impacts of the novel CoronaVirus. We’d like to see our FDA cleared nebulizer make an impact, particularly for the patients we already serve - those with chronic respiratory conditions such as asthma and COPD. We’re enhancing our production and distribution strategies to include delivery of COVIDCare Kits that package a 7-day disposable supply for our nebulizer. We are also working on a retooled version of our AireHealth mobile app to track COVID-19 symptoms and communicate status to caregivers and physicians as required.

Seeking Collaborators for COVID-19 Response (By AireHealth)
  • +5 months
  • Hide post

New use for an existing drug as antiviral agent against SARS-CoV-2 to prevent or/and treat COVID-19

CSIC has discovered a new use for an existing drug on the market as antiviral agent. Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement.

New use for an existing drug as antiviral agent against SARS-CoV-2 to prevent or/and treat COVID-19
  • +04 hours
  • Hide post

SARS-CoV-2 Targeted Libraries for offer

Protease-Oriented SARS-CoV-2 Library (1017 Compounds) - Developed by Virtual Receptor-Based Screening Using the Crystal Structure of the Basic SARS-CoV-2 Protease (PDB ID: 6LU7) ML (Machine Learning) SARS-target library (1577 compounds) - carefully developed using machine learning (artificial neural networks and Bayesian statistics).

SARS-CoV-2 Targeted Libraries for offer
  • +1 month
  • Hide post

Viral RNA-dependent RNA Polymerases

Viral RNA-dependent RNA Polymerases (RdRPs) Targeted Library (1259 compounds) with predicted activity against viral RdRPs is offered. It has been carefully designed using machine learning (artificial neural networks and Bayesian statistics

Viral RNA-dependent RNA Polymerases
  • +1 month
  • Hide post

SARS-CoV-2 RNA-dependent RNA Polymerase Targeted Library

OtavaResearch Institute group presents SARS-CoV-2 RNA-dependent RNA Polymerase Targeted Library (1031 in-stock compounds with predicted activity against SARSCoV2 (RdRpp)).

SARS-CoV-2 RNA-dependent RNA Polymerase Targeted Library
  • +1 month
  • Hide post

SARS-CoV-2 Papain-like ProteaseTargeted Library

Using receptor based virtual screening OtavaResearchInstitute’s team designed the SARS-CoV-2 Papain-like Protease PLpro Targeted Library, which is contain 1058 stock compounds with predicted activity against this protease and ready for delivery.

SARS-CoV-2 Papain-like ProteaseTargeted Library
  • +1 month
  • Hide post

SARS-CoV-2 NSP16 Targeted Library

SARS-CoV-2 2′-O-methyltransferase (NSP16) Targeted Library, which contains 1049 compounds with predicted activity against SARS-CoV-2 NSP16 is offered. The library has been designed with receptor-based virtual screening using crystal structure of SARS-CoV-2 2′-O-MTase (PDB ID: 6WKQ).

SARS-CoV-2 NSP16 Targeted Library
  • +1 month
  • Hide post

SARS-CoV-2 Helicase Targeted Library

The offer SARS-CoV-2 Helicase (NSP13) Targeted Library, which contain 1170 compounds with predicted activity against this vital protein. The overall procedure included accurate flexible docking of Drug-like Green Collection into helicase active site.

SARS-CoV-2 Helicase Targeted Library
  • +1 month
  • Hide post

A Novel Therapeutic Approach Targeting Coronavirus Replication-Essential RNAs by Oligonucleotides

A Novel Therapeutic Approach Targeting Coronavirus Replication-Essential RNAs by Oligonucleotides. The research team plans to develop a drug to inhibit human SARS-CoV-2 replication. They will use comparative genomics to detect conserved regions within the coronavirus family, and within human CoV-19 population, in order to identify essential genes that can be targeted to inhibit the virus replication. Project ID : 47-2020-10912

A Novel Therapeutic Approach Targeting Coronavirus Replication-Essential RNAs by Oligonucleotides
  • +2 months
  • Hide post

The Use of Chip Scale Photonics for the Advanced, and Efficient Detection of Viruses

The Use of Chip Scale Photonics for the Advanced, and Efficient Detection of Viruses Chip scale photonics technology is developing rapidly for diverse applications, from communication and computation to various types of sensing. The Levy group has pioneered diverse advanced chip scale photonic technologies, including for example low loss waveguides, high Q resonators, cutting edge filtering capabilities, integration of active and passive device on chip, and the manufacturing of hybrid chips bringing together microfluidics and photonic devices. Project ID : 47-2020-10886

The Use of Chip Scale Photonics for the Advanced, and Efficient Detection of Viruses
  • +2 months
  • Hide post

Active Masks with Virus Neutralizing Properties

Active Masks with Virus Neutralizing Properties Professors Willner and Pikarsky are developing masks and possible ventilation systems that will contain virus neutralizing properties. They have undertaken the development of matrices that neutralize pathogens which can be incorporated into fabrics, paper, or nonreactive particles such as silica or alumina. Project ID : 47-2020-10888

Active Masks with Virus Neutralizing Properties
  • +2 months
  • Hide post

Relieving Lung disease in COVID-19 Patients with Aerosols that Carry Viral Genes Inhibitors

Relieving Lung disease in COVID-19 Patients with Aerosols that Carry Viral Genes Inhibitors Step One: “Smart” micro - or nano-particles carrying inhibitors of the gene machinery in pathogens are developed. Step Two: In the presence of biomarkers, the inhibiting agents are released, leading to the localized destruction of the pathogens. Project ID : 47-2020-10887

Relieving Lung disease in COVID-19 Patients with Aerosols that Carry Viral Genes Inhibitors
  • +2 months
  • Hide post

5-MER Peptide to Ameliorate Coronavirus-Induced Inflammation of the Upper Respiratory Tract and Lungs

5-MER Peptide to Ameliorate Coronavirus-Induced Inflammation of the Upper Respiratory Tract and Lungs This study will test the hypothesis that treatment with a peptide comprising five units (5-MER), which is administered by injection or oral delivery, will substantially reduce chronic inflammation of the upper respiratory tract and lungs, thus ameliorating the effects of the Coronavirus disease. This will be achieved by targeting a major pro-inflammatory protein called SAA which plays an active role in the development of the disease. Furthermore, it is anticipated that the 5-MER peptide may also activate genes that provide resistance to chronic inflammation mediated by Coronavirus. Project ID : 47-2020-10890

5-MER Peptide to Ameliorate Coronavirus-Induced Inflammation of the Upper Respiratory Tract and Lungs
  • +2 months
  • Hide post

High-Throughput Sequencing Methods to Test Samples

Highly parallel test for the presence of SARS-CoV-2 The currently used test for SARS-CoV2 virus uses molecular methods for detecting the presence of viral RNA sequences in subject samples. This is the approved gold standard in the field. The current application of this test requires several cumbersome steps that are labor intensive and require non-trivial reagents (which are becoming a global bottleneck). It is clear that during the next stage of managing the COVID19 pandemic, large scale testing will be needed. Project ID : 47-2020-10893

High-Throughput Sequencing Methods to Test Samples
  • +2 months
  • Hide post

Novel Activating Antibodies for Viral Treatment

Novel Activating Antibodies for Viral Treatment Various pathogens (bacteria and viruses as well) bind to specific cell adhesion molecule in order to inhibit the immune response and/or to infect the host cells. However,upon binding and induction/activation, the cell adhesion molecule suppresses virus production by an SHP2-dependent process which involves also suppression of mTOR-mediated protein biosynthesis. Project ID : 47-2020-10898

Novel Activating Antibodies for Viral Treatment
  • +2 months
  • Hide post

Rapid Computational Screening of Natural Products for COVID-19 Anti-Viral Agents

Some edible compounds are potent antiviral agents and were tested successfully against SARS and MERS viruses. They hence provide an large source for rapid development and production of cure against COVID-19. These compounds are commercially available, and are generally recognized as safe (GRAS), with a vast chemical diversity. Despite the high-level genetic similarity to other coronaviruses, such as SARS-CoV and MERS-CoV, recent works demonstrate major structural differences in SARS-CoV2 (the causal agent of COVID-19 disease) proteins. The need for specific anti-SARS-COV2 treatments is acute. Rapid screening of the food derived compounds, using chemoinformatic modeling tools that are common in our lab, allow the identification of a small number of potent antiviral candidate inhibitors of recent published SARS-CoV2 target proteins. Project ID : 47-2020-10884

Rapid Computational Screening of Natural Products for COVID-19 Anti-Viral Agents
  • +2 months
  • Hide post

Plant-based Diagnostic Kit to Detect Sick and Recovered SARS-CoV-2 Virus Patients

Genetically modified plant systems that allow identification of SARS-CoV-2 RNA and anti-SARS-CoV-2 antibodies Applications Preventing the spread of the epidemic Restoring economic activity by returning immune-positive, symptomless people to work Features System can be rapidly reproduced through seeds Essentially unlimited quantities, extremely inexpensive Can be used in any environment No need for special machinery Adaptable to other diseases Project ID : 47-2020-10883

Plant-based Diagnostic Kit to Detect Sick and Recovered SARS-CoV-2 Virus Patients
  • +2 months
  • Hide post

Using Peptide Nucleic Acids (PNAs) as a Tool to Diagnose COVID-19

Using Peptide Nucleic Acids (PNAs) as a Tool to Diagnose COVID-19 We offer a fast and efficient diagnostic method which can be applied to a large amount of tests in a short time. Our method is based on a kit which identifies specifically the viral RNA biomarker. The test is characterized by reliability, sensitivity, rapid (not more than 10-15 minutes), low toxicity and reasonable cost. Project ID : 47-2020-10881

Using Peptide Nucleic Acids (PNAs) as a Tool to Diagnose COVID-19
  • +2 months
  • Hide post

Systematic Computational Drug Repositioning to Treat COVID-19

Systematic Computational Drug Repositioning to Treat COVID-19 The genetic revolution which has taken place in recent years brings new opportunities to the field of drug discovery & repositioning. Using advanced comparative genomic, and data integration, our lab has been developing a state-of-the-art AI algorithm which maps drug and food supplements that are useful in treating diseases and improving health conditions. To create this algorithm, we have been integrating and analyzing massive amounts of genomic data from 1,600 genomes, 14 thousand compounds, 20,000 human genes, and a comprehensive database of phenotypic data. Project ID : 47-2020-10880

Systematic Computational Drug Repositioning to Treat COVID-19
  • +2 months
  • Hide post

Screening of Drugs to Inhibit Viral Infections

Our group has published a lot of work on the SARS Coronavirus. We were the first to characterize an important protein in the virus that has a very unusual structure and sequence (E protein). Moreover, this protein was unique to SARS and was not found in any other Coronavirus. Now importantly, the new 2019 Coronavirus has a very similar protein! Project ID : 47-2020-10879

Screening of Drugs to Inhibit Viral Infections
  • +2 months
  • Hide post

A Unique Platform for Curing Coronavirus and Similar Lethal Diseases

A Unique Platform for Curing Coronavirus and Similar Lethal Diseases A Unique Platform for Curing Coronavirus and Similar Lethal Diseases Project ID : 47-2020-10878

A Unique Platform for Curing Coronavirus and Similar Lethal Diseases
  • +2 months
  • Hide post

Fooling the Virus: A Fusion Protein as Virus-Specific Therapeutic

Fooling the Virus: The Fusion protein as Virus-Specific Therapeutic An ACE2 A fusion protein of ACE2 with an Immunogenic Component Project ID : 47-2020-10877

Fooling the Virus: A Fusion Protein as Virus-Specific Therapeutic
  • +2 months
  • Hide post

Deciphering the Virus-Host Tango: Understanding network of interactions through evolution, structure, dynamics, and computational design

Deciphering the Virus-Host Tango: Understanding network of interactions through evolution, structure, dynamics, and computational designProject ID : 47-2020-10875

Deciphering the Virus-Host Tango: Understanding network of interactions through evolution, structure, dynamics, and computational design
  • +2 months
  • Hide post

Using Signature Genes to Detect Early-Stage Coronavirus and Predict Individual Outcomes

Using Signature Genes to Detect Early-Stage Coronavirus and Predict Individual Outcomes Project ID : 47-2020-10876 Test signature genes of host for non-invasive and early detection of Coronavirus infection, even before the infected person is symptomatic (also allowing differentiation from influenza virus infections). Moreover, this unique signature can be used to predict disease outcome in infected individuals as well as predict the vulnerability to the virus in non- infected individuals. The last can be valuable for screening of vulnerable populations such as medical teams and caregivers.

Using Signature Genes to Detect Early-Stage Coronavirus and Predict Individual Outcomes
  • +2 months
  • Hide post

Early warning system for detecting deterioration in post intensive care patients

In the UK 28% of deaths in patients treated on an Intensive Care Unit (ICU) occur after the patients return to the general ward. These patients often suffer late developing complications after initial successful treatment in the ICU. There is usually a period of deterioration when a patient shows some signs of developing a complication. PICRAM (Post Intensive Care Risk Adjusted Monitoring) is a system that watches over the electronic records of the vital signs of patients after discharge from an ICU. It analyses the information to estimate the likelihood that a patient will suffer a complication in the next 24-48 hours. Patients most at risk of complications can then be identified and specialist nurses sent to start treatment early to the patients who need them most. The early detection of deterioration provided by PICRAM can save lives and reduce treatment costs.

Early warning system for detecting deterioration in post intensive care patients
  • +3 months
  • Hide post

S-PACES. People and vehicle monitoring IoT system to control confinement and healthcare measures during COVID-19

People and vehicle monitoring IoT system to control confinement and healthcare measures during COVID-19. With this SmartCities Solution, the goal is to have a tool capable of knowing the movements of people and vehicles in different parts of the city. In this way, it will be possible to evaluate compliance with the measures adopted and implement improvements in them, if necessary.

S-PACES. People and vehicle monitoring IoT system to control confinement and healthcare measures during COVID-19
  • +4 months
  • Hide post

Shimmer3 Bioimpedance Monitor - Monitoring HR, respiration rate and depth, and the increase in fluid in the lungs to triage and remotely monitor Covid-19 patients

Managing the huge influx of patients in hospitals is one of the most critical challenges of the current COVID-19 pandemic. Shimmer’s Bioimpedance Monitor has the potential to help manage this challenge by monitoring HR, respiration rate and depth and the increase in fluid in the lungs to triage and remotely monitor patients. Background Bioimpedance, specifically across the lungs, has long been studied in Chronic Heart Failure (CHF) and Acute Respiratory Distress Syndrome (ARDS). This measurement provides useful indicators of respiration, including rate, volume, and fluid in the lungs. Because COVID-19 attacks the lungs, these measurements provide clear indications of the progression of the disease. This information can be used in many ways, potentially including: • Monitoring patients remotely at home to determine, if and when, they will need to be admitted to the hospital • Monitoring patients in a hospital to determine when they need more aggressive treatment (e.g., ventilators) • Enabling the earlier release of non-acute patients because of the ability to monitor at home • Adjusting the treatment depending on the rate of progression of disease

Shimmer3 Bioimpedance Monitor - Monitoring HR, respiration rate and depth, and the increase in fluid in the lungs to triage and remotely monitor Covid-19 patients
  • +5 months
  • Hide post

COVID-19 Rapid Diagnostic Kit

Designing and developing vaccines, cures and diagnostic kits can be considered as the first priority for every country which is in the first line of fighting against coronavirus. Now there is only PCR test and IgG/IgM test for COVID-19 assessment. One of the most important problems of this diagnostic test is the time needed by the device to detect infected persons. This problem makes big companies in the field of pharmaceutical and medical devices manufacturing to design and develop rapid test kits. Our research team found that there are some specific proteins on the viral membrane which can make some reagents undergo a specific chemical reaction. Every reaction has a specific product related to substrates, so by detection of products with indicator reagents we are able to identify the virus in saliva. Indicator reagents usually change the reaction mixture color so by color change we can approve that the person is infected by COVID-19.

COVID-19 Rapid Diagnostic Kit
  • +6 months
  • Hide post

Expertise in molecular biology either experimentally or computationally

The Institut de Biotecnologia i de Biomedicina (IBB) was created in 1970 as a research institute of the Universitat Autònoma de Barcelona (UAB) to promote fundamental biological research. In the year 2000, the focus of research evolved towards the Biotechnology and Biomedicine fields, with the aim of advancing scientific findings into translational results. At present, the Institute hosts 18 research groups organised into 3 programmes and working in 7 areas of expertise: • Bioinformatics • Cellular Biology • Structural Biology • Genomics • Immunology • Microbiology • Proteomics. This multidisciplinary character, one of the most relevant characteristics of the IBB, allows for a broad approach to biological problems, both basic and applied. The IBB is also highly engaged in academic training at the undergraduate and postgraduate levels.

Expertise in molecular biology either experimentally or computationally
  • +6 months
  • Hide post

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors

A series of small pharmacological molecules have been discovered to be potent and non-cytotoxic inhibitors of viral fusion. The inhibitors act on the non-virally encoded lipids in the virion envelope. These molecules are rigid amphipathic compounds of inverted cone shape which locate to the outer leaflets of virion envelopes, creating a physical barrier to viral envelope and cell membrane fusion. These amphipathic nucleoside derivatives can serve as potential antiviral or therapeutic agents against herpes, HIV, influenza, hepatitis B & C, poxvirus and other DNA or RNA enveloped viruses. They can potentially be used as prophylactic ingredients in creams, lotions, gels and as antiviral disinfectants.

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors
  • +6 months
  • Hide post

Alphanosos rapid discovery technology against COVID 19

Alphanosos’ AI guided rapid discovery technology, validated in antimicrobials and anticancer, is expected to develop within 3 weeks of experimental work with a virology partner an anti-COVID-19 treatment composed of a synergistic mix of extracts of edible plants, chosen for being available in large amounts and with good traceability. Such treatment is, therefore, and also thanks to the innovative elaboration process, immediately available to enter large curative clinical trials, to be followed by country-wide deployment in a matter of weeks, for curative and for preventive goals (because of safety which is guaranteed by the edible nature of the mix).

Alphanosos rapid discovery technology against COVID 19
  • +6 months
  • Hide post

Latest News

Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting

Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting

Published on 17 September, 2020

--- This article was originally published on the press room portal at lilly.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- - Primary endpoint of viral load change from baseline at day 11 was met for one of three doses; consistent effects of viral reduction seen at earlier time points - Rate of hospitalizations and ER visits was 1.7 percent (5/302) for LY-CoV555 ...
  • +2 weeks
  • Hide post
NIH researchers investigate virulence of SARS-CoV-2 virus

NIH researchers investigate virulence of SARS-CoV-2 virus

Published on 25 June, 2020

--- This article was originally published by Samantha Black, PhD, The Science Advisory Board staff writer on the digital media scienceboard.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- What makes the SARS-CoV-2 virus so virulent? Researchers from the U.S. National Institutes of Health (NIH) analyzed the genomics of the virus -- and compared it to other coron...
  • +3 months
  • Hide post
Sexton, BioSpherix collaborate to support cell & gene therapy needs

Sexton, BioSpherix collaborate to support cell & gene therapy needs

Published on 25 June, 2020

--- This article was originally published by The Science Advisory Board staff writers on the digital media scienceboard.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- Sexton Biotechnologies is partnering with BioSpherix Medical on the final steps of downstream bioprocessing, fill-finish. Sexton's off-the-shelf fill system, the Sexton Biotechnologies AF-500, ...
  • +3 months
  • Hide post
Ideaya and GSK partner on synthetic lethality programs

Ideaya and GSK partner on synthetic lethality programs

Published on 25 June, 2020

--- This article was originally published by The Science Advisory Board staff writers on the digital media scienceboard.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- Ideaya Biosciences and GlaxoSmithKline (GSK) have formed a strategic partnership in the emerging oncology field of synthetic lethality. Synthetic lethality occurs when the combination of two or...
  • +3 months
  • Hide post
Lilly begins phase III trial for COVID-19 therapy

Lilly begins phase III trial for COVID-19 therapy

Published on 19 June, 2020

--- This article was originally published by The Science Advisory Board staff writers on the digital media scienceboard.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- Eli Lilly has enrolled patients in a phase III study to evaluate the efficacy and safety of baricitinib in hospitalized adults with COVID-19. Baricitinib, marketed by the company as Olumiant, i...
  • +3 months
  • Hide post
Are interferons helpful or harmful during SARS-CoV-2 infection?

Are interferons helpful or harmful during SARS-CoV-2 infection?

Published on 19 June, 2020

--- This article was originally published by Samantha Black, PhD, The Science Advisory Board staff writer on the digital media scienceboard.net. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- The host immune system produces a variety of regulatory molecules, including interferons (IFNs), during a response to viral infection. Although previously considered beneficial,...
  • +3 months
  • Hide post
Scanning for answers to a pandemic

Scanning for answers to a pandemic

Published on 11 June, 2020

--- This article was originally published by Bill Gates on the digital media gatesnotes.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- A new surveillance program in Seattle is detecting cases of COVID-19 and helping guide public health responses. In any fight, it’s important to know your enemy. Unfortunately, in our battle against COVID-19, there’s a lot ...
  • +3 months
  • Hide post
Covid-19 Vaccine Generates Immune Response

Covid-19 Vaccine Generates Immune Response

Published on 11 June, 2020

--- This article was originally published by Alan on the digital media sciencebusiness.technewslist.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- First results from a clinical trial testing a vaccine to protect against Covid-19 infections show the vaccine produces an immune response in healthy participants. The trial, conducted by National Institute of Allergy ...
  • +3 months
  • Hide post
Announcing the COVID-19 Therapeutics Accelerator

Announcing the COVID-19 Therapeutics Accelerator

Published on 05 May, 2020

--- This article was originally published by Mark Suzman on the digital media gatesfoundation.org. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- The first time I ever wrote about global health was an article on the looming AIDS crisis in my native South Africa. My piece for the Johannesburg Star in 1991 reported dire predictions from experts about the potential of...
  • +4 months
  • Hide post
31 questions and answers about COVID-19: My thoughts on what to do now and other topics

31 questions and answers about COVID-19: My thoughts on what to do now and other topics

Published on 05 May, 2020

--- This article was originally published on March 19, 2020, by Bill Gates on the digital media gatesnotes.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- Yesterday I did a Reddit Ask Me Anything session on COVID-19. As usual, Redditors asked a lot of smart questions, and it was a great opportunity to have a fact-based discussion about this pandemic and what we...
  • +4 months
  • Hide post
COVID-19 clean-up will threaten EU digital and green goals

COVID-19 clean-up will threaten EU digital and green goals

Published on 05 May, 2020

--- This article was originally published on April 21, 2020, by Éanna Kelly on the digital media sciencebusiness.net. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- EU regional commissioner says Europe should not ‘destroy path we’re on’, but accepts demand for future funding will be dominated by post-pandemic rebuilding The EU commissioner who oversees reg...
  • +4 months
  • Hide post
Global leaders unite to ensure everyone everywhere can access new vaccines, tests and treatments for COVID-19

Global leaders unite to ensure everyone everywhere can access new vaccines, tests and treatments for COVID-19

Published on 05 May, 2020

--- This article was originally published on April 24, 2020 on the digital media who.int. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- Unprecedented gathering of heads of government, institutions and industry cements commitment to accelerate development and delivery for all populations Heads of state and global health leaders today made an unprecedented commitm...
  • +4 months
  • Hide post
Open Innovation and Multiparty Cooperation in Biotechnology and Pharmaceuticals: Alternative Measures in Times of Public Emergency

Open Innovation and Multiparty Cooperation in Biotechnology and Pharmaceuticals: Alternative Measures in Times of Public Emergency

Published on 04 May, 2020

--- This article was originally published on April 20, 2020, by HERDEM Attorneys at Law on the digital media lexology.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- The race for finding a cure for COVID-19 continues, as more research centers, private enterprises and universities around the globe concentrate on finding an antiviral or vaccine against the virus o...
  • +4 months
  • Hide post
Open innovation for Covid-19 crisis

Open innovation for Covid-19 crisis

Published on 04 May, 2020

--- This article was originally published on April 21, 2020, by Dr. Sheetal Menon on the digital media forbesindia.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- There is a need for collective and coordinated scientific undertakings on a global scale to rapidly expedite the development pipeline for drugs, vaccines, and diagnostics “We need our collective k...
  • +4 months
  • Hide post
Q BioMed Partner Mannin Research Developing Potential Treatment for Patients Infected with Coronavirus and Other Infectious Diseases

Q BioMed Partner Mannin Research Developing Potential Treatment for Patients Infected with Coronavirus and Other Infectious Diseases

Published on 16 April, 2020

--- This article was originally published on April 2, 2020, by Financial Buzz on the digital media financialbuzz.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- – Preclinical data show unique platform addresses vascular leakage, which may support the health of patients during coronavirus infection – Platform has been awarded grants from Canada and Europe...
  • +5 months
  • Hide post
From Vaccines to Testing, M2D2 is ‘Laser-Focused’ on the Coronavirus

From Vaccines to Testing, M2D2 is ‘Laser-Focused’ on the Coronavirus

Published on 16 April, 2020

--- This article was originally published on March 3, 2020, by Ed Brennen on University of Massachusetts Lowell's media portal. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- The announcement came in late June 2018, just as many people were turning their attention to Fourth of July cookouts and summer vacation plans. The federal agency tasked with solving critica...
  • +5 months
  • Hide post
Franz Fayot launches new aid linked to the development and production of products in the fight against Covid-19 for an envelope of 30 million euros

Franz Fayot launches new aid linked to the development and production of products in the fight against Covid-19 for an envelope of 30 million euros

Published on 15 April, 2020

--- This article was originally published on April 4, 2020, by The Ministry of the Economy on Meco.gouvernement.lu. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- As part of the economic stabilization program, the Government Council approved on April 8 on a proposal from the Minister of the Economy, Franz Fayot, an aid scheme to support both industrial research proj...
  • +5 months
  • Hide post
Pitt and UPMC roll out revolutionary way to test COVID-19 drugs

Pitt and UPMC roll out revolutionary way to test COVID-19 drugs

Published on 15 April, 2020

--- This article was originally published on April 9, 2020, 5 p.m by David Templeton  post-gazette.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- The overriding question in treating COVID-19 is whether such drugs as hydroxychloroquine or remdesivir — or multiple other drugs in the research pipeline — will make a difference? So University of Pittsb...
  • +5 months
  • Hide post

Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

Published on 14 April, 2020

Issued: London, UK Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine  Candidate vaccine expected to enter clinical trials in the second half of 2020 and, if successful, to be available in the second half of 2021 Sanofi and GSK today announce that they have signed a letter of intent to enter into a collaboration to develop an adjuvanted vaccine for COVID-19, using innovative technology from both c...
  • +5 months
  • Hide post
Top Kitchenware Provider Lifetime Brands Talks Coronavirus And Open Innovation

Top Kitchenware Provider Lifetime Brands Talks Coronavirus And Open Innovation

Published on 12 April, 2020

--- This article was originally published on April 8, 2020, by Stephen Key on Forbes.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. ---- The cancelation and postponement of massive trade events like the international housewares show in Chicago and national hardware show in Las Vegas have resulted in many unanswered questions. At these one-of-a-kind annual meeting ...
  • +5 months
  • Hide post
Opinion: What is the role of innovation in COVID-19 response?

Opinion: What is the role of innovation in COVID-19 response?

Published on 12 April, 2020

------ This article was originally published on April 7, 2020, by  David Milestone  on Devex.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. ------ Crises generate a lot of energy that, if harnessed constructively, can be a great source of innovation. The COVID-19 response is producing inspiring innovative responses proving that, indeed, necessity is the mothe...
  • +5 months
  • Hide post
The Global Patent Race for a COVID-19 Vaccine

The Global Patent Race for a COVID-19 Vaccine

Published on 30 March, 2020

--- This article was originally published on March 24, 2020, by Rebeca Harasimowicz on the digital version of The National Law Review. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- As COVID-19 is causing chaos around the globe, the world’s largest economies are competing to be the first to find a cure to this new pandemic and taking measures to ensure that their...
  • +6 months
  • Hide post
Impact of the Corona crisis on startups & tech

Impact of the Corona crisis on startups & tech

Published on 26 March, 2020

OOn top of the human toll, the Corona crisis is an economic shock, unlike anything we’ve seen for a long time. Retail, mobility, and travel are especially hit. Other sectors are outperforming the market: food delivery, online groceries, telehealth, streaming, gaming and video conferencing. Zoom is now worth more than Uber. Should Lyft acquire its own food delivery business to weather the storm? Eventually, the recovery will come. Which sta...
  • +6 months
  • Hide post
Coronavirus will show VCs’ true colours

Coronavirus will show VCs’ true colours

Published on 25 March, 2020

--- This article was originally published on March 23, 2020, by Matt Clifford on Sifted.eu. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- Most of us in the startup community pride ourselves on knowing something about exponential growth. Even so, it’s been hard to take in how quickly coronavirus has changed the landscape in the last couple of weeks. Unfortunatel...
  • +6 months
  • Hide post
Innovation Imperatives from Covid-19

Innovation Imperatives from Covid-19

Published on 23 March, 2020

--- This article was originally published on March 18, 2020 by Henry Chesbrough, Contributor, at the online version of Forbes. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- With some delay, we humans are beginning to marshal our counter-attack against the coronavirus. Some nascent but promising developments across a number of areas are worth noting, for they sket...
  • +6 months
  • Hide post
The state of Open Innovation

The state of Open Innovation

Published on 23 March, 2020

--- This article was originally published on March 20, 2020 by Irving Wladawsky-Berger, at the online version of the Wall Street Journal. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- Firms today recognize that there are more capabilities for innovation in the marketplace than what they can possibly create on their own. This open innovation model, the antithesis o...
  • +6 months
  • Hide post

About

Ahead of the current Coronavirus outbreak, Innoget is fully committed to contributing to mobilizing scientific and expert communities to find a real solution to the Covid-19 pandemic. Therefore, we're supporting worldwide calls and programs that could help in any aspects of the coronavirus crisis.

Is your organization promoting or looking for innovation or research initiatives to mitigate the Covid-19 outbreak? Email us at covid19@innoget.com to list them.

Channeled through Innoget's online open innovation network, initiatives in the health, virology, medicine, or novel technologies applied to human health, among others, are listed and disseminated to Innoget members -ranging from hospitals, research institutes, scientists, businesses, and public administrations- and innovation partners worldwide.

Contact person

Jordi Ràfols

CEO at Covid-19 Innovation Challenges by Innoget
https://www.innoget.com/group/covid-19-open-innovation-initiative
–
Hospital & Health Care
11-50 employees
Innovation Intermediary
2020
United Kingdom

About our Innovation Strategy

Innoget connects you and your team to 175,000+ decision-makers around the world, providing access to hundreds of innovation and research opportunities you will find nowhere else to solve actual challenges. Being the partner of choice for thousands of organizations to generate new projects connecting with verified partners, Innoget has become the reference for effective online open innovation and technology transfer due to its leading platform Innoget.com. Innoget.com provides integrated open innovation and technology transfer functionalities and services to both easily externalize and internationalize your scientific and technological offer, as well as to introduce you to hundreds of exclusive innovation needs published by our community of businesses.

Research areas (8)

Applications for HealthBiological SciencesMedicine, Human HealthClinical Research, TrialsMedical Research and 3 more

Latest Job Offers

Covid-19 Innovation Challenges by Innoget has't published any job offer yet

Latest Events

Infectious Diseases Virtual 2020

14 - 15 June, 2020

VA, USA

WCID 2020 Conference invites all the Nobel laureates, speakers, delegates, Infectious Diseases Specialists from all over the world to attend Infectious Diseases virtual 2020 webinar which is scheduled on June 14, 2020. These conferences prompt keynote presentations, Oral talks, Poster presentations. Infectious Diseases virtual 2020 is dedicated to recent investigation and Improving Access in the treatment of infectious diseases. It will deliver n...
  • +3 months

#EUvsVirus Challenge

24 - 26 April, 2020

Online

The European Commission, in close collaboration with the EU member states, will host a pan-European hackathon to connect civil society, innovators, partners and investors across Europe in order to develop innovative solutions for coronavirus-related challenges. Now is your chance to help tackle coronavirus! When? 24, 25 and 26 April EUvsVirus Hackathon euvsvirus.org is a Europe-wide online hackathon organized by the most plugged in and n...
  • +5 months

COVID19 Global Forecasting (Week 4)

12 - 16 April, 2020

Online

This is week 4 of Kaggle's COVID-19 forecasting series, following the Week 3 competition. This is the 4th competition we've launched in this series. All of the prior discussion forums have been migrated to this competition for continuity. Background The White House Office of Science and Technology Policy (OSTP) pulled together a coalition research groups and companies (including Kaggle) to prepare the COVID-19 Open Research Dataset (CORD-19...
  • +5 months

LaFutura x virtual edition

30 April, 2020 - 30 April, 2020

Online

The country-specific part of the network and its activities is called „LaFutura x“. Every active country offers its members up to four local events per year – each with a different future focus. With the virtual edition we want to bring together thoughts from around the world with less impact on the planet. No travels required, less time invest for you and still a global network of forward-thinkers! Our topic: Social Disruption Wha...
  • +5 months

LUMIATA COVID-19 GLOBAL AI HACKATHON

17 April, 2020 - 01 May, 2020

Limiata

Lumiata invite data scientists, machine learning practitioners, developers, health IT professionals, public health experts and others around the globe, to participate in the Lumiata COVID-19 Global AI Hackathon. Participants will develop solutions that address the challenges this pandemic poses to citizens of the world today and for the impact it will have in the future. Winners will be recognized with solutions fully open-sourced and hosted on t...
  • +5 months

#code19 Hackathon Against Covid19

10 - 11 April, 2020

India

Decode Coronavirus, its impact and implications for India and its citizens. Encode Smart solutions to mitigate the India’s impending Covid19 challenges. Win prizes worth US$10,000 to realize your solutions. CODE19 is a 72hrs online hackathon event to find immediate solutions to India’s challenges against the menace of Coronavirus. CODE19 is open to all and requires no registration fee to participate. Silicon Valley based Motwani Jadeja Founda...
  • +5 months

Galen Growth Webinar: HealthTech Deal Factory & Special Fireside Chat with DXY: Tackling the nCoV outbreak

06 April, 2020 - 06 April, 2020

Online

We are delighted to confirm your spot at the Galen Growth webinar, on the 6th April 2020, where select startups will be pitching their business roadmap to investors and corporates and connect via a late afternoon networking session. This special Deal Factory session will close with a unique Fireside Chat with Stanley Li, CEO & Founder of DXY on tackling the nCoV outbreak: Integrating digital technology and public health in China....
  • +5 months

Free Webinar: COVID-19 - Protection - Management - POCUS

27 March, 2020 - 27 March, 2020

Online

We invite you to participate in or next free webinar: COVID-19: Protection – Diagnosis – Treatment Shanghai – Vienna – Paris – Dallas We will discuss: The current situation in China, France, the US and Austria Preventive measures for Health Care Professionals The role of Point of Care US / lung ultrasound No webinar registration required. Do you want to actively share your experience during the Webinar? Contact us at thomas.binder@123so...
  • +6 months

Infectious Disease Outbreak Research: Insights and Trends

30 March, 2020 - 30 March, 2020

Online

Over the past two decades, the world has faced several infectious disease outbreaks. Ebola, Influenza A (H1N1), SARS, MERS, Zika virus and, most recently, COVID-19, have had a massive global impact in terms of economic disruption, strain on local and global public health resources and, above all, human health. Please join us for this webinar as Dr. Bamini Jayabalasingham explains how the research was conducted to uncover trends in outbreaks re...
  • +6 months

Survive and Thrive: The Coronavirus Crisis

25 March, 2020 - 25 March, 2020

Warwick, United Kingdom

Free live webinar for business owners, managers, decision makers and employees. About this Event ‘Survive and thrive’ is a webinar to prepare you and your business for the positive and negative impacts of the coronavirus crisis. In this uncertain time, one thing is guaranteed – as rapidly as the market place changes due the coronavirus crisis, so too must your business. Business Growth Specialist Kevin Riley will take you step by step throu...
  • +6 months

Coronavirus / COVID-19: Risk Mitigation Webinar - Part 2

24 March, 2020 - 24 March, 2020

Illinois, United States

This follow-up webinar shares updates on the issues and initiatives associated with effective risk mitigation efforts of COVID-19. About this Event As the impacts of the novel coronavirus/COVID-19 continue to change, join us for Part 2 of the Coronavirus / COVID-19: Risk Mitigation Webinar. This session will feature effective risk mitigation efforts to protect your company, employees and customers based on recent developments. Our experts will in...
  • +6 months

Virtual Meeting: Engineering Discussions Related to the Coronavirus

26 March, 2020 - 26 March, 2020

California, United States

California engineers are invited to this discussion about coronavirus and engineering About this Event NSPE-CA Vice President Joseph Quinn will be hosting an online meeting to discuss coronavirus and engineering. NSPE Virtual Meeting – Engineering Discussion Related to the Coronavirus Thu, Mar 26, 2020 11:00 AM - 12:00 PM (PDT) Please join my meeting from your computer, tablet or smartphone. https://global.gotomeeting.com/join/567962285 You can...
  • +6 months

CoronaHack - AI vs. Covid-19

18 April, 2020 - 18 April, 2020

London, United Kingdom

A virtual hackathon bringing together Biomedical and data scientists to explore ways to combat CoronaVirus. About this Event Please join us for this high profile hackathon designed to accelerate approaches to monitoring, diagnosing and controlling the CoronaVirus. This event will shortly go virtual through a platform with full access to covid-19 datasets and other technology. You will work collaboratively with top data scientists, biomedical rese...
  • +5 months

Related profiles

Innoget © 2020 Innoget